Evidence map›Paper›PMID 28223543›Full record

ArticleOncotarget2017

Role of caspases in CD95-induced biphasic activation of acid sphingomyelinase.

Mario Stephan, Bärbel Edelmann, Supandi Winoto-Morbach, Ottmar Janssen, Uwe Bertsch, Cristiana Perrotta, Stefan Schütze, Jürgen Fritsch

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Targeting the Sphingolipid Rheostat in Gliomas.International journal of molecular sciences · 2022
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Mario StephanInstitute of Immunology, Christian-Albrechts-University of Kiel, Kiel, Germany.
Bärbel EdelmannDepartment of Hematology and Oncology, University Hospital Magdeburg, Magdeburg, Germany.
Supandi Winoto-MorbachInstitute of Immunology, Christian-Albrechts-University of Kiel, Kiel, Germany.
Ottmar JanssenInstitute of Immunology, Christian-Albrechts-University of Kiel, Kiel, Germany.
Uwe BertschInstitute of Immunology, Christian-Albrechts-University of Kiel, Kiel, Germany.
Cristiana PerrottaDepartment of Biomedical and Clinical Sciences "Luigi Sacco" (DIBIC), Università degli Studi di Milano, Milano, Italy.
Stefan SchützeInstitute of Immunology, Christian-Albrechts-University of Kiel, Kiel, Germany.
Jürgen FritschInstitute of Immunology, Christian-Albrechts-University of Kiel, Kiel, Germany.
Kiel University · DEUniversity Hospital Magdeburg · DEUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acid sphingomyelinase (A-SMase) plays an important role in the initiation of CD95 signaling by forming ceramide-enriched membrane domains that enable clustering and activation of the death receptors. In TNF-R1 and TRAIL-R1/R2 signaling, A-SMase also contributes to the lysosomal apoptosis pathway triggered by receptor internalization. Here, we investigated the molecular mechanism of CD95-mediated A-SMase activation, demonstrating that A-SMase is located in internalized CD95-receptosomes and is activated by the CD95/CD95L complex in a biphasic manner.Since several caspases have been described to be involved in the activation of A-SMase, we evaluated expression levels of caspase-8, caspase-7 and caspase-3 in CD95-receptosomes. The occurrence of cleaved caspase-8 correlated with the first peak of A-SMase activity and translocation of the A-SMase to the cell surface which could be blocked by the caspase-8 inhibitor IETD.Inhibition of CD95-internalization selectively reduced the second phase of A-SMase activity, suggesting a fusion between internalized CD95-receptosomes and an intracellular vesicular pool of A-SMase. Further analysis demonstrated that caspase-7 activity correlates with the second phase of the A-SMase activity, whereas active caspase-3 is present at early and late internalization time points. Blocking caspases-7/ -3 by DEVD reduced the second phase of A-SMase activation in CD95-receptosomes suggesting the potential role of caspase-7 or -3 for late A-SMase activation.In summary, we describe a biphasic A-SMase activation in CD95-receptosomes indicating (I.) a caspase-8 dependent translocation of A-SMase to plasma membrane and (II.) a caspase-7 and/or -3 dependent fusion of internalized CD95-receptosomes with intracellular A-SMase-containing vesicles.

Indexed as

ApoptosisB-LymphocytesCaspase InhibitorsCaspasesCell MembraneCell ProliferationEnzyme ActivationFas Ligand Proteinfas ReceptorHumansSignal TransductionSphingomyelin PhosphodiesteraseTumor Cells, CulturedCaspase InhibitorsCaspasesFas Ligand Proteinfas ReceptorSphingomyelin Phosphodiesteraseacid sphingomyelinaseCD95 ligandCD95-receptosomesceramideinternalization

Identifiers

PMID28223543
PMCPMC5386744
OpenAlexW2590119755

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.